Cover Image
市場調查報告書

創傷後壓力症候群 (PTSD) 治療藥的全球市場:2015∼2019年

Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 333551
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
創傷後壓力症候群 (PTSD) 治療藥的全球市場:2015∼2019年 Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019
出版日期: 2015年06月24日 內容資訊: 英文 71 Pages
簡介

創傷後壓力症候群 (PTSD) 是暴露於某種創傷,感情上衰弱後發病的心理學症狀。PTSD無論任何年齡男女都可能發生,治療上進行心理學諮詢。某種外傷曝曬非理智地了之後的哪個也不問能被進行。全球PTSD市場,預計以2014∼2019以年複合成長率1.09%擴大。

本報告提供全球PTSD治療藥市場相關詳細分析、市場趨勢與2015∼2019年的成長預測、產品概要、各類藥物、各地區趨勢、及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

第4章 市場調查方法

第5章 產品簡介

  • Paxil/Seroxat
  • Zoloft

第6章 簡介

第7章 PTSD概要

  • PTSD的理解
  • 病因
  • 症狀
  • 診斷
  • 管理
  • PTSD的自助治療
  • 流行病學
  • 經濟負擔

第8章 開發平台分析

  • 開發中產品資訊

第9章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 各類藥物市場區隔

  • 抗憂鬱劑
  • 抗不安劑
  • 其他

第11章 各地區市場區隔

第12章 購買標準

第13章 市場成長的促進要素

第14章 促進要素與其影響

第15章 市場課題

第16章 促進要素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 供應商環境

  • 競爭模式
  • 市場佔有率調查:2014年
  • 其他未來預計處於的供應商

第20章 PTSD治療藥的全球市場

第21章 主要供應商調查

  • GlaxoSmithKline
  • 大塚製藥株式會社
  • Pfizer

第22章 本系列的其他報告

目錄
Product Code: IRTNTR6225

About PTSD

PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA), PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • Otsuka Pharmaceutical

Other Prominent Vendors

  • Azevan Pharmaceuticals
  • Baylor Research Institute
  • Eli Lilly
  • Forest Laboratories
  • H. Lundbeck
  • Humanetics Pharmaceuticals
  • Marinus Pharmaceuticals
  • Nanotherapeutics
  • Neurocrine Biosciences
  • Novartis Pharmaceuticals
  • Synchroneuron
  • Tonix Pharmaceuticals

Market Driver

  • Growing Number of Accidents and Violence Worldwide
  • For a full, detailed list, view our report

Market Challenge

  • Unavailability of Standard Diagnostic Methods
  • For a full, detailed list, view our report

Market Trend

  • Rise in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

  • 05.1. Paxil/Seroxat
  • 05.2. Zoloft

06. Introduction

07. PTSD Overview

  • 07.1. Understanding the Disorder
  • 07.2. Etiology and Pathogenesis
  • 07.3. Signs and Symptoms
    • 07.3.1. Re-experiencing Symptoms
    • 07.3.2. Avoidance Symptoms
    • 07.3.3. Arousal Symptoms
  • 07.4. Diagnosis
  • 07.5. Management
    • 07.5.1. Psychotherapy
    • 07.5.2. Pharmacotherapy
  • 07.6. Self-Help Treatment of PTSD
  • 07.7. Epidemiology
  • 07.8. Economic Burden

08. Pipeline Analysis

  • 08.1. Information on Pipeline Candidates
    • 08.1.1. Brexpiprazole
    • 08.1.2. Iloperidone
    • 08.1.3. NBI-77860/GSK-561679
    • 08.1.4. At-Ease
    • 08.1.5. PRX-3140
    • 08.1.6. SNC-102
    • 08.1.7. TNX-102 SL
    • 08.1.8. Ganaxolone
    • 08.1.9. SRX251 and SRX246
    • 08.1.10. Doxazosin
    • 08.1.11. pep-EphrinA4

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Class of Drug

  • 10.1. Antidepressant Drugs
    • 10.1.1. SSRIs
    • 10.1.2. SNRIs
    • 10.1.3. Tricyclic Antidepressants
    • 10.1.4. MAO Inhibitors
  • 10.2. Anti-anxiety Drugs
    • 10.2.1. Benzodiazepines
    • 10.2.2. Beta-blockers
  • 10.3. Others
    • 10.3.1. Atypical Antipsychotics
    • 10.3.2. Anticonvulsants
    • 10.3.3. Alpha-1 Receptor Antagonists
    • 10.3.4. Alpha-2 Adrenergic Agonists

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Analysis 2014
    • 19.2.1. Pfizer
    • 19.2.2. GlaxoSmithKline
    • 19.2.3. Otsuka Pharmaceutical
  • 19.3. Other and Future Prominent Vendors

20. Global PTSD Therapeutics Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. GlaxoSmithKline
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2014
    • 21.1.4. Business Segmentation by Revenue 2013 and 2014
    • 21.1.5. Geographical Segmentation by Revenue 2014
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Otsuka Pharmaceutical
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue 2014
    • 21.2.4. Business Segmentation by Revenue 2013 and 2014
    • 21.2.5. Geographical Segmentation by Revenue 2014
    • 21.2.6. Business Strategy
    • 21.2.7. Recent Developments
    • 21.2.8. SWOT Analysis
  • 21.3. Pfizer
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2014
    • 21.3.4. Business Segmentation by Revenue 2013 and 2014
    • 21.3.5. Geographical Segmentation by Revenue 2014
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis

22. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Events Leading to PTSD
  • Exhibit 3: Treatment Options for PTSD
  • Exhibit 4: Prevalence of PTSD among Women in US
  • Exhibit 5: Global Prevalence of PTSD by Gender
  • Exhibit 6: Pipeline Portfolio of PTSD Drugs
  • Exhibit 7: Global PTSD Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 8: Segmentation of Global PTSD Therapeutics Market by Class of Drug
  • Exhibit 9: Segmentation of Global PTSD Therapeutics Market by Region 2014
  • Exhibit 10: Major Drivers of Global PTSD Therapeutics Market
  • Exhibit 11: Major Challenges in Global PTSD Therapeutics Market
  • Exhibit 12: Major Trends in Global PTSD Therapeutics Market
  • Exhibit 13: Global PTSD Therapeutics Market Analysis 2014
  • Exhibit 14: Pfizer: YoY Growth and Revenue of Zoloft 2010-2014 ($ millions)
  • Exhibit 15: Pfizer: Revenue of Zoloft by Region 2010-2014 ($ millions)
  • Exhibit 16: GlaxoSmithKline: YoY Growth and Revenue of Paxil 2010-2014 ($ millions)
  • Exhibit 17: GlaxoSmithKline: Revenue of Paxil by Region 2010-2014 ($ millions)
  • Exhibit 18: Global PTSD Therapeutics Market: Key Takeaways
  • Exhibit 19: GlaxoSmithKline: Business Segmentation by Revenue 2014
  • Exhibit 20: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 21: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
  • Exhibit 22: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
  • Exhibit 23: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 ($ millions)
  • Exhibit 24: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 26: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 27: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top